Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?

Intuitive Surgical shares have fallen roughly 29% year to date as da Vinci procedure-growth slowed to 15% in the latest quarter from 17% in Q4 2025; full-year growth is forecast at 13.5%-15.5%. Headwinds include lower U.S. bariatric procedure volumes linked to GLP-1 drugs, expired ACA-plan subsidies, and intensifying robotic-surgery competition from Johnson & Johnson, Medtronic, and Chinese rivals. Despite these risks, 24 of 32 analysts surveyed rate the stock buy/strong buy, with an average 12-month target implying 18% upside and a Bernstein target implying 70% upside.

Analysis

The key equity issue is not a modest deceleration in procedures, but whether investors must reset ISRG from a premium growth-medtech multiple to a mature capital-equipment multiple. Because recurring instruments and service revenue are tied to installed-base utilization, sustained low-teens procedure growth would pressure both forward revenue revisions and the valuation premium simultaneously. Conversely, a stable capital pipeline would indicate that utilization softness is not yet becoming an installed-base expansion problem.

The GLP-1 exposure is likely more nuanced than the market’s first-order read: lower bariatric intervention volumes are a real offset, but reduced obesity-related surgical demand does not impair the broader urology, gynecology, thoracic, and general-surgery opportunity. The more material 6-18 month risk is hospital purchasing behavior: if payer uncertainty constrains elective-care budgets, customers can defer robot placements even while existing-system procedure utilization remains resilient. JNJ and MDT benefit strategically from any perceived opening in robotic surgery, but their diversified earnings bases make them poor pure-play shorts against ISRG.

Near-term, the stock remains vulnerable into the next procedure-volume update because consensus positioning appears constructive and any guide-down could trigger another multiple leg lower. A better entry requires evidence that procedure growth is stabilizing within management’s range, U.S. capital orders remain intact, and China competition is not causing price concessions. The contrarian opportunity is that the market may be extrapolating a narrow bariatric and reimbursement headwind into a broad impairment of robotic-surgery adoption; that thesis is falsified if non-bariatric growth also weakens or recurring-revenue growth decouples from the installed base.

Key Decisions for Investors

• Do not chase ISRG on analyst-target support alone; place a 1-3 month watch entry around the next earnings/procedure update. Initiate a half-sized long only if procedure growth holds within guidance and capital-order commentary remains stable; exit if management cuts procedure guidance or flags pricing pressure in China.
• For a defined-risk bullish expression, consider an ISRG 6-9 month call spread after results rather than outright stock ahead of the print. The thesis requires a stabilization signal; absent that signal, implied-volatility and guidance risk make pre-earnings long calls unattractive.
• Use a small tactical long ISRG / short IHI pair only after confirmation of stable utilization, isolating company-specific recovery from broad medtech multiple risk. Reassess over 3-6 months; close if recurring revenue growth slows materially relative to procedure growth or hospitals begin deferring placements.
• Avoid treating JNJ or MDT as immediate earnings beneficiaries. Monitor robotic-system placement disclosures, surgeon adoption data, and any competitive pricing commentary over the next 2-4 quarters; a verified share-gain signal would support a longer-duration JNJ or MDT overweight, not a near-term event trade.